It is well known that hip fractures are associated with significant morbidity and mortality: Mortality increases 15–25% in the year following a hip fracture.1–5 We know that treating osteoÂporosis prevents fractures and improves patient survival. But is there a relationship beyond this? Several studies have found that bisphosphonate therapy is associated with a reduction in…
The ACR, in concert with the Vasculitis Foundation, released three new vasculitis guidelines online first in July, with a fourth slated for publication by the end of the year. These are the first ever to be produced and endorsed by the ACR and the Vasculitis Foundation. Although most of the recommendations are conditional, due to…
NEW YORK (Reuters Health)—Results of a randomized controlled trial do not support routine use of proactive therapeutic drug monitoring (TDM) during infliximab induction for improving disease remission rates in patients rheumatoid arthritis (RA) and other chronic immune-mediated inflammatory diseases. Proactive therapeutic drug monitoring tailors biologic therapy to individual patients by measuring serum drug levels and…
The new Twitter account enables quick communication between ACR advocacy staff and ACR/ARP members about the policies, regulations and legislation that affect rheumatology patients and providers and how members can get involved.
At a virtual event with the chair of the Ways & Means Subcommittee on Health, RheumPAC donors were able to share concerns and recommendations about drug pricing policies and how they affect providers and patients.
The ACR is advocating against policies that threaten patient access and disrupt practice workflow, including non-medical switching, tapering patients off biologics, specialty pharmacy acquisition mandates and site-of-service restrictions.
Bright spots from this legislative session include utilization management reform, copay accumulator bans and pharmacy benefit manager reform.
Learn to properly use the revised CPT codes to document your time and medical decision making during patient visits to help ensure your practice is appropriately remunerated.
New research into the symptom heterogeneity of patients with post-treatment Lyme disease may serve as a framework to create targeted interventions or novel treatments for these patients.